CN115485301A - 治疗癌症的组合物和方法 - Google Patents

治疗癌症的组合物和方法 Download PDF

Info

Publication number
CN115485301A
CN115485301A CN202180031794.6A CN202180031794A CN115485301A CN 115485301 A CN115485301 A CN 115485301A CN 202180031794 A CN202180031794 A CN 202180031794A CN 115485301 A CN115485301 A CN 115485301A
Authority
CN
China
Prior art keywords
binding agent
cancer
ser
domain
chimeric binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180031794.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·切列什
S·维斯
S·麦考马克
C·雷德
H·韦特斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Beta Holdings LLC
Original Assignee
Alpha Beta Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Beta Holdings LLC filed Critical Alpha Beta Holdings LLC
Publication of CN115485301A publication Critical patent/CN115485301A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180031794.6A 2020-04-23 2021-04-23 治疗癌症的组合物和方法 Pending CN115485301A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014550P 2020-04-23 2020-04-23
US63/014,550 2020-04-23
PCT/US2021/028775 WO2021216956A1 (en) 2020-04-23 2021-04-23 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
CN115485301A true CN115485301A (zh) 2022-12-16

Family

ID=78270118

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180031794.6A Pending CN115485301A (zh) 2020-04-23 2021-04-23 治疗癌症的组合物和方法

Country Status (12)

Country Link
US (1) US20230140868A1 (https=)
EP (1) EP4110822A4 (https=)
JP (1) JP7817948B2 (https=)
KR (1) KR20230019424A (https=)
CN (1) CN115485301A (https=)
AU (1) AU2021261003A1 (https=)
BR (1) BR112022019939A2 (https=)
CA (1) CA3172092A1 (https=)
IL (1) IL296576A (https=)
MX (1) MX2022013207A (https=)
PH (1) PH12022553129A1 (https=)
WO (1) WO2021216956A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113330035A (zh) * 2019-01-10 2021-08-31 Sg医疗株式会社 抗β1整合素人源化抗体以及包含其的用于治疗癌症的药学组合物
WO2024174744A1 (zh) * 2023-02-24 2024-08-29 恒翼生物医药(上海)股份有限公司 抗αvβ3抗体和抗PD-1抗体的联合药物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020145669A1 (ko) 2019-01-10 2020-07-16 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
WO2023056326A1 (en) * 2021-09-30 2023-04-06 Alpha Beta Holdings, Llc Compositions and methods for treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030152571A1 (en) * 1997-03-12 2003-08-14 Smithkline Beecham Corporation Anti-alphabeta3 humanized monoclonal antibodies
US20060040325A1 (en) * 2004-08-16 2006-02-23 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
CN105451767A (zh) * 2013-03-15 2016-03-30 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2018183894A1 (en) * 2017-03-31 2018-10-04 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
WO2002055106A2 (en) * 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
BR112013026828A2 (pt) * 2011-04-21 2016-11-29 Bristol Myers Squibb Co polipeptídeos de anticorpo que antagonizam cd40
CA2881981A1 (en) * 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2015134988A1 (en) * 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030152571A1 (en) * 1997-03-12 2003-08-14 Smithkline Beecham Corporation Anti-alphabeta3 humanized monoclonal antibodies
US20060040325A1 (en) * 2004-08-16 2006-02-23 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
CN105451767A (zh) * 2013-03-15 2016-03-30 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2018183894A1 (en) * 2017-03-31 2018-10-04 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
F MITJANS ET AL.: "An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice", 《J CELL SCI》, 31 August 1995 (1995-08-31), pages 2825 - 2838, XP002615476 *
HIROMI I ET AL.: "Targeting integrin αvβ3-expressing cancer stem cells to manipulate tumor-associated macrophages", 《CANCER RES》, 1 July 2017 (2017-07-01) *
KATHY MULGREW ET AL.: "Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin", 《MOL CANCER THER》, vol. 5, no. 12, 30 November 2006 (2006-11-30), pages 3122 - 3129, XP055859734, DOI: 10.1158/1535-7163.MCT-06-0356 *
TONG ZHANG ET AL.: "The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions", 《CANCER IMMUNOLOGY, IMMUNOTHERAPY》, 23 April 2018 (2018-04-23), pages 1079 - 1090, XP036529047, DOI: 10.1007/s00262-018-2160-x *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113330035A (zh) * 2019-01-10 2021-08-31 Sg医疗株式会社 抗β1整合素人源化抗体以及包含其的用于治疗癌症的药学组合物
CN113330035B (zh) * 2019-01-10 2024-08-13 Sg医疗株式会社 抗β1整合素人源化抗体以及包含其的用于治疗癌症的药学组合物
WO2024174744A1 (zh) * 2023-02-24 2024-08-29 恒翼生物医药(上海)股份有限公司 抗αvβ3抗体和抗PD-1抗体的联合药物

Also Published As

Publication number Publication date
BR112022019939A2 (pt) 2022-12-13
WO2021216956A1 (en) 2021-10-28
MX2022013207A (es) 2023-01-24
JP7817948B2 (ja) 2026-02-19
US20230140868A1 (en) 2023-05-11
IL296576A (en) 2022-11-01
EP4110822A1 (en) 2023-01-04
AU2021261003A1 (en) 2022-10-20
EP4110822A4 (en) 2024-04-10
CA3172092A1 (en) 2021-10-28
PH12022553129A1 (en) 2024-02-26
KR20230019424A (ko) 2023-02-08
JP2023523016A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
JP7724061B2 (ja) 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用
US20260098089A1 (en) Antagonist anti-cd7 antibodies
JP2024063176A (ja) 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法
IL296673A (en) Anti-ccr8 antibodies for cancer treatment
CN110545844A (zh) 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗
JP7817948B2 (ja) がんを処置するための組成物および方法
CN114181310B (zh) 抗tigit抗体、其药物组合物及用途
TW201011045A (en) Anti-CD5 antibodies
JP2021503927A (ja) Ｃｄ４７抗体及びがんを治療するためのその使用
CN110392694A (zh) 针对pd-1的抗体及其用途
TR201900368T4 (tr) Csf1r'ye bağlanan antikorlar.
JP2022509065A (ja) ヒト化抗ＳＩＲＰα抗体
WO2022188832A1 (zh) 含有抗pd-1-抗vegfa双特异性抗体的药物组合及其用途
WO2019047885A1 (en) IMMUNOCONJUGATES COMPRISING ALPHA REGULATORY SIGNAL PROTEIN
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
JP2023513059A (ja) 抗ミューラー管ホルモン受容体２抗体及び使用方法
CN118284622A (zh) 治疗癌症的组合物和方法
US20220265821A1 (en) Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas
US12077597B2 (en) Anti-CD5 antibodies and methods of use thereof
KR102955590B1 (ko) 인간화 항-SIRPα 항체
WO2024040150A1 (en) Binding agents targeting gd2 and their use for treating cancer
HK40120124A (zh) 抗ccr8抗体及其用途
WO2024054418A1 (en) Sequence optimization of a pd1 blocking antibody
HK40101629A (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
HK40120378A (zh) 针对ceacam5和cd47的双特异性抗体与针对ceacam5和cd3的双特异性抗体的组合治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination